Rocket


Overview
Financials
News + Filings
Key Docs
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Apellis Pharmaceuticals, Inc. (APLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE ® in the Third Quarter of 2023"
08/22/2023 8-K Other Events  Interactive Data
07/31/2023 8-K Quarterly results
07/17/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/15/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/24/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C",
"Form of Pre-Funded Warrant",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants"
01/09/2023 8-K Quarterly results
01/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/24/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/02/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Exchange Agreement",
"Form of Exchange Agreement"
07/27/2022 8-K Quarterly results
07/19/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
03/16/2022 8-K Other Events  Interactive Data
01/10/2022 8-K Investor presentation
Docs: "Excerpt from corporate presentation dated January 2022"
11/17/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock"
09/09/2021 8-K Quarterly results
08/30/2021 8-K Quarterly results
08/19/2021 8-K Quarterly results
07/26/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock"
07/08/2021 8-K Quarterly results
06/30/2021 8-K Other Events  Interactive Data
06/01/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
01/26/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock"
01/07/2021 8-K Quarterly results
01/04/2021 8-K Quarterly results
10/27/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments"
06/01/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/13/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even...
05/07/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Capped Call Transaction Confirmation",
"Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes"
04/06/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/09/2020 8-K Entry into a Material Definitive Agreement, Other Events  Interactive Data
Docs: "Underwriting Agreement, by and among the Company and Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Evercore Group L.L.C",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy